Carmichael J, Bessell E M, Harris A L, Hutcheon A W, Dawes P J, Daniels S, Bessel E M
CRC Academic Unit of Clinical Oncology, Nottingham City Hospital Trust, UK.
Br J Cancer. 1994 Dec;70(6):1161-4. doi: 10.1038/bjc.1994.465.
Two hundred and seventy-eight adult chemonaive patients, receiving moderately emetogenic chemotherapy were randomly allocated to receive either intravenous (i.v.) granisetron 3 mg plus i.v. dexamethasone 8 mg or i.v. granisetron 3 mg plus i.v. placebo dexamethasone prior to chemotherapy. Eight-two per cent of all patients recruited were female, and 91% of all patients consumed less than 10 units of alcohol per week, suggesting a study population with an increased risk of nausea and vomiting. In the first 24 h 85% of patients who received granisetron plus dexamethasone were complete responders compared with 75.9% of the patients receiving granisetron alone (P = 0.053). There were statistically significant improvements in complete response over 7 days (P = 0.029) and in the numbers of patients receiving rescue antiemetic (P = 0.0004). Toxicity was minimal with no significant differences between treatment groups. These results confirm the antiemetic activity of granisetron and show that it has an additive effect in combination with dexamethasone.
278名未曾接受过化疗的成年患者接受中度致吐性化疗,在化疗前被随机分配接受静脉注射3毫克格拉司琼加静脉注射8毫克地塞米松,或静脉注射3毫克格拉司琼加静脉注射安慰剂地塞米松。所有招募患者中82%为女性,91%的患者每周饮酒量少于10个单位,这表明研究人群恶心和呕吐风险增加。在最初24小时内,接受格拉司琼加地塞米松的患者中85%为完全缓解者,而仅接受格拉司琼的患者为75.9%(P = 0.053)。在7天内完全缓解率有统计学显著改善(P = 0.029),接受解救性止吐药治疗的患者数量也有统计学显著改善(P = 0.0004)。毒性极小,治疗组之间无显著差异。这些结果证实了格拉司琼的止吐活性,并表明它与地塞米松联合使用有相加作用。